Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

View All Documentation

A7655

Sigma-Aldrich

Atenolol

≥98% (TLC), powder, β₁-adrenoceptor antagonist

Sinonimo/i:

(±)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide, 4-[2′-Hydroxy-3′-(isopropylamino)propoxy]phenylacetamide

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C14H22N2O3
Numero CAS:
29122-68-7
Peso molecolare:
266.34
Numero CE:
249-451-7
Numero MDL:
MFCD00057645
Codice UNSPSC:
12352200
ID PubChem:
24277748
NACRES:
NA.77

product name

Atenolol, ≥98% (TLC), powder

Saggio

≥98% (TLC)

Forma fisica

powder

Colore

white to off-white

Solubilità

H2O: 0.3 mg/mL
DMSO: 18 mg/mL
ethanol: 3.4 mg/mL

Ideatore

AstraZeneca

Stringa SMILE

CC(C)NCC(O)COc1ccc(CC(N)=O)cc1

InChI

1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
METKIMKYRPQLGS-UHFFFAOYSA-N

Informazioni sul gene

human ... ADRB1(153)
rat ... Adrb1(24925)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

Atenolol is a β-adrenergic blocker and used in the management of hypertension. Atenolol has antianginal and antiarrhythmic properties.

Azioni biochim/fisiol

Selective β1-adrenoceptor antagonist; antihypertensive; antianginal; antiarrhythmic.

Caratteristiche e vantaggi

This compound is featured on the β-Adrenoceptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Altre note

Shelf-life of the solid is at least three years.

Applicazioni

N° Catalogo
Descrizione
Determinazione del prezzo

Standard

N° Catalogo
Descrizione
Determinazione del prezzo

06613

Atenolol-d7, analytical standard

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Gloves, type N95 (US)

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 6

1 of 6

(+/-)-Atenolol

Sigma-Aldrich

5.05416

(+/-)-Atenolol

ICI 118,551 hydrochloride ≥98% (HPLC), powder

Sigma-Aldrich

I127

ICI 118,551 hydrochloride

Carvedilol ≥98% (HPLC), solid

Sigma-Aldrich

C3993

Carvedilol

Atenolol-d7 analytical standard

Supelco

06613

Atenolol-d7

Nadolol analytical standard

Supelco

N1892

Nadolol

oleic acid(17-yne) Avanti Research™ - A Croda Brand 900412E, ethanol solution

Avanti

900412E

oleic acid(17-yne)

Ganesha Rai et al.
Journal of medicinal chemistry, 52(20), 6474-6483 (2009-09-19)
Schistosomiasis is a chronic parasitic disease affecting hundreds of millions of individuals worldwide. Current treatment depends on a single agent, praziquantel, raising concerns of emergence of resistant parasites. Here, we continue our explorations of an oxadiazole-2-oxide class of compounds we
Hsin-Hui Chiu et al.
Mayo Clinic proceedings, 88(3), 271-276 (2013-01-17)
To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to β-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS). Between May 1, 2007, and September 31
Ronald V Lacro et al.
American heart journal, 165(5), 828-835 (2013-04-30)
The Pediatric Heart Network designed a clinical trial to compare aortic root growth and other short-term cardiovascular outcomes in children and young adults with Marfan syndrome randomized to receive atenolol or losartan. We report here the characteristics of the screened
Sripal Bangalore et al.
The American journal of medicine, 127(10), 939-953 (2014-06-15)
Debate exists about the efficacy of β-blockers in myocardial infarction and their required duration of usage in contemporary practice. We conducted a MEDLINE/EMBASE/CENTRAL search for randomized trials evaluating β-blockers in myocardial infarction enrolling at least 100 patients. The primary outcome
Ronald V Lacro et al.
The New England journal of medicine, 371(22), 2061-2071 (2014-11-19)
Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers. We conducted a randomized trial comparing
Visualizza tutti i documenti correlati

Chromatograms

application for HPLC

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.